📅 Updated June 2026🕒 10 min read✓ Medically Reviewed
🭺
Written by the Luma Health Medical Team. Medically reviewed by Christina Bertoni, APRN. Luma Health competes with Hims and stands to benefit if you choose Luma Health.
Editorial Disclosure & Methodology
This page identifies complaint patterns from publicly available patient reviews (Reddit, BBB, Trustpilot) and documented business changes as of June 2026. Hims is a legitimate, publicly traded company (NYSE: HIMS) — these are structural friction points and business model changes, not evidence of fraud or unsafe practice.
The Most Common Hims GLP-1 Complaints — With Context
Hims is one of the largest GLP-1 telehealth platforms and by volume serves more patients than most competitors. The complaints below are patterns, not isolated incidents, and each has structural context worth understanding.
① Compounded Tirzepatide Discontinued, Compounded Semaglutide in Flux Major 2026 Change
The most significant recent change at Hims: compounded tirzepatide has been discontinued entirely. Hims now sells brand-name Zepbound instead, at approximately $1,899/month — a substantial increase for patients who enrolled expecting compounded pricing. Separately, Hims' compounded semaglutide program was affected by a public dispute with Novo Nordisk in early 2026; the dispute was settled in March 2026 with Hims signing a direct supply deal, and Hims is transitioning toward branded Wegovy/Ozempic (~$299/month self-pay). Compounded semaglutide availability going forward should be verified directly, as it may be limited or discontinued.
What to do about it:
If you were on Hims' compounded tirzepatide, that option is gone — confirm your current status directly at hims.com and compare brand Zepbound pricing against compounded alternatives elsewhere. Luma Health offers compounded tirzepatide at $297/month flat, a small fraction of Hims' current brand-name Zepbound price.
② Pharmacy Not Disclosed for Independent Verification Hims-Specific
Hims does not prominently name its specific compounding pharmacy partner(s) in consumer-facing materials. Patients who want to independently verify their medication's source find this difficult without contacting support.
What to do about it:
Contact Hims support directly and ask for the pharmacy's name and state board license number in writing. For comparison, Luma Health publicly names VialsRX (TX #35264), verifiable at pharmacy.texas.gov.
③ Slow or Difficult Customer Support Response Industry-Wide
Delayed support response is the most common complaint category across GLP-1 telehealth at scale — not unique to Hims. Their support team handles volume across sexual health, hair loss, skincare, mental health, and weight loss simultaneously.
What to do about it:
For non-urgent questions, use async messaging and allow 48–72 hours. For urgent clinical concerns, contact your PCP or urgent care rather than waiting for telehealth response.
④ Cancellation Friction and Auto-Renewal Charges Industry-Wide
Difficulty canceling — or discovering subscriptions auto-renewed despite attempted cancellation — is a common complaint across multiple platforms, not unique to Hims.
What to do about it:
Initiate cancellation at least 5–7 days before your billing date. Request written email confirmation with the effective date. Screenshot the confirmation screen.
⑤ Shipping Delays and Medication Arrival Timing Industry-Wide
Shipping delays around billing cycles and high-demand periods are reported across multiple platforms including Hims, due to cold-chain packaging and pharmacy preparation time.
What to do about it:
Order refills when you have 2–3 doses remaining, not at your last dose. Track your shipment actively and contact support if delayed.
Hims is a generalist multi-condition platform — weight loss is one category alongside sexual health, hair, skincare, and mental health. Provider interactions are primarily asynchronous, with no video consultations for GLP-1.
What to do about it:
Supplement with your PCP or a registered dietitian specializing in GLP-1 patients for complex clinical questions.
What Hims Does Well — The Genuine Strengths
✓ Hims' Genuine Clinical and Platform Strengths
NYSE-listed public company (HIMS) — institutional stability
Multi-condition platform — convenient for patients using Hims for other services too
Polished app experience — weight tracking, provider messaging, subscription management in one interface
Fast onboarding — provider review typically within 24–48 hours
If You're Currently Having a Problem With Hims
1
Unexpected billing charge: Screenshot the charge, check for plan change notifications, contact Hims support with the specific charge date and amount.
2
Shipping delay: Check tracking in the Hims app. If no tracking after 10 business days, contact support and request a status update.
3
Clinical question not getting answered: For urgent concerns, contact your PCP. For non-urgent questions, send a written message and allow 48–72 hours.
4
Cancellation difficulty: Navigate to account settings → subscription management. Request written confirmation with effective date.
5
Considering switching providers: Start your new provider's intake before canceling Hims to avoid a medication gap.
Compounded tirzepatide. Still $297/mo flat.
No dose surprises. VialsRX (TX #35264). No contracts.
Yes. Hims (NYSE: HIMS) is a publicly traded telehealth company with licensed clinical infrastructure. The complaints documented here are structural friction points and business model changes — not safety or legitimacy concerns.
No. Hims discontinued compounded tirzepatide entirely and now sells brand-name Zepbound instead, at approximately $1,899/month. Patients who want compounded tirzepatide need to look elsewhere — Luma Health offers it at $297/month flat.
Availability is uncertain following a 2026 dispute with Novo Nordisk and Hims' subsequent transition toward branded Wegovy/Ozempic (~$299/month self-pay). Verify current compounded semaglutide availability directly at hims.com before enrolling.
Cancel at least 5–7 days before your next billing date. Follow the cancellation flow completely, request written email confirmation with the effective date, and screenshot the confirmation screen.
If you were on compounded tirzepatide, that option is gone at Hims — Luma Health's $297/month flat compounded tirzepatide is a direct, far less expensive alternative to Hims' current brand Zepbound pricing. For pharmacy transparency, Luma Health names VialsRX (TX #35264) publicly, which Hims does not.
References
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed 33567185
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024
FDA. Human Drug Compounding — Section 503A. FDA.gov
Better Business Bureau. Hims & Hers Health Business Profile. bbb.org
NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov
Medical Disclaimer: This article documents structural complaint patterns and business model changes reported as of June 2026. It does not constitute a safety warning — Hims is a legitimate telehealth platform. Luma Health competes with Hims — readers should consider our competitive bias. Clinical services at Luma Health are provided by Wasef Health, PC. Compounded medications prepared by VialsRX, TX Board #35264.